Impax Laboratories — Merger or Acquisition (June 2016)
19 slides from Impax Laboratories's merger presentation, Jun 21, 2016
Slide 1: Impax Announces Agreement to Acquire Generic Products
Impax Announces Agreement to Acquire Generic Products : June 21, 2016
Slide 2: Cautionary Statement Regarding Forward Looking Statements
Impax Cautionary Statement Regarding Forward Looking Statements safe Harbor” statement under the Private Securities Litigation Reform Act of 1995; To the extent any statements made in this presentation contain information that is not historical; these statements are forward-looking in nature and exp
Slide 3: Agenda
Agenda fee = red Wilkinson - President & CEO | * Strategic and Financial Benefits of Acquisition fee Cryan Reasons - SVP & CFO | + Updated 2016 Full Year Financial Guidance eee = Fred Wilkinson * Strategic Priorities and Future Growth Drivers me = Executive Team + Q&A
Slide 4: Expanding Portfolio with Acquisition of Generic Products
Expanding Portfolio with Acquisition of Generic Products Fred Wilkinson President and CEO
Slide 5: Acquisition Fits With Strategic Priorities
Acquisition Fits With Strategic Priorities Compelling Strategic Benefits Compelling Financial Benefits | + Adds broad generic portfolio of solid + Immediately accretive to earnings per oral, inhalable, injectable and topical diluted share dosage forms + Diversifies and enlarges revenue and >» 18gene
Slide 6: Transaction Overview
Transaction Overview Purchase Price and = $586 million in cash Considerations to, Cigsing subject to customary closing conditions and Closing = Approval by the Federal Trade Commission (FTC) of Impax as buyer = Closing of Teva's acquisition of Allergan’s U.S. generics business Financing e Existing c
Slide 7: Expands Currently Marketed Generic Portfolio
Expands Currently Marketed Generic Portfolio Adding 15 Marketed Products Increases Portfolio by31% to (% of 2015 Revenues by Dosage Form) 64 Products . ~ 15 Solid Oral* 43 35% —_— Differentiated Portfolio Across i Multiple Dosage Forms OtherSOD "Controle-Release Alternative Dosage SOD Form 1 Current
Slide 8: Valuable Pipeline of Future Opportunities
Valuable Pipeline of Future Opportunities ion Adds In Addition to Marketed Products, Acqui + 1 approved product and 2 approved strengths of a currently marketed productnot yet launched + 1 pipeline productand 1 pipeline strength of a currently marketed product pending at FDA * 1 product under develo
Slide 9: Acquisition Delivers in Our Primary Areas of Focus
Acquisition Delivers in Our Primary Areas of Focus Focus on Quality and Operations + Utilizes available manufacturing capacity + Reduces manufacturing conversion costs Maximize + Expands currently marketed portfolio Dual Platform + Adds limited-competition products + Expands product pipeline Optimiz
Slide 10: Updated 2016 Full Year Financial Guidance
Updated 2016 Full Year Financial Guidance Bryan Reasons SVP and CFO The Company's fll year 2016 estimates are based on management's curent expectations, including the incorporation ofall the acqvired products and assuming the transaction closes by June. 30. 2046. curent prescription trends" prcing I
Slide 11: Acquisition Expected to Provide Significant Boost to 2016 Earnings
Acquisition Expected to Provide Significant Boost to 2016 Earnings + Immediately accretive acquisition + Additional competition on diclofenac sodium gel and metaxalone more than offset by > Acquisition of higher-margin products > Potential upside on a few higher-margin existing base business product
Slide 12: Updated 2016 Financial Guidance Summary
Updated 2016 Financial Guidance Summary (incorporating all acquisition products) Prior Guidance Updated Guidance Revenue Increase at least 15% over full year 2015 No change Adjusted gross margin Approximately 50% Low 50% range ‘R&D and patent Tiisetlon Gonenes Approximately $100 to $105 million No c
Slide 13: Well-Positioned Capital Structure Post-Acquisition
Well-Positioned Capital Structure Post-Acquisition Significant Financial Resources and Flexibility to Support Growth Estimated Capitalization Leverage ($ millions) Net Debt Cash and Cash Equivalents — $412 Net Debt / LTM Adjusted March 31, 2016 EBITDA Less cash used for acquisition $ 186 Revolver ($
Slide 14: Strategic Priorities and Future Growth Drivers
Strategic Priorities and Future Growth Drivers Fred Wilkinson President and CEO
Slide 15: Since Mid-2014 Delivered Results Across Our Four Strategic Areas
Since Mid-2014 Delivered Results Across Our Four Strategic Areas Fosuson + Resolved Warning Letter in Hayward CTTNACGINN —~ Improved operational efficiencies and restructured R&D - annual savings of approx. $12MM Operations * Closing Middlesex, NJ manufacturing and packaging facility in 2017 that wi
Slide 16: Multiple Opportunities to Drive Future Growth
Multiple Opportunities to Drive Future Growth (incorporating all acquisition products) + Gross margin expansion currently expected in 2017 + Approximately $23MM to $27MM in annual operational savings from Middlesex, NJ facility closure + Increased utilization and lower conversion costs as a result o
Slide 17: Q&A
Slide 18: Appendix
Appendix
Slide 19: Pending ANDAs at FDA
22 Pending ANDAs at FDA Product Strengths Brand | IMS Sales Colesevelam IR tablet 625mg Welchol® 642M Dutasteride/Tamsulosin IR capsule 0.5 mgi0.4 mg Jalyn® Tem z 40 mg/10 mg, 10 mg/20mg, Ezetimibe Simvastatin IR tablet oe eee Fiore) $702M April 2017 Fenofibric Acid DR capsule * 45, 195 mg Trlipix®
Impax Laboratories — Merger or Acquisition (June 2016) on 6ix